Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
| Autor: | B. Douglas Smith, Monica Mead, Michal G. Rose, Jessica K. Altman, Leland Metheny, Ravi Bhatia, Michael W. Deininger, Mrinal M. Patnaik, Moshe Talpaz, Joseph O. Moore, Kendra Sweet, Kiran Naqvi, Lori J. Maness, Arnel Pallera, Sanjay R. Mohan, Gabriela S. Hobbs, Bhavana Bhatnagar, James E. Thompson, Daniel J. DeAngelo, Kristina M. Gregory, Keith W. Pratz, David T. Yang, Ellin Berman, Neil P. Shah, Hema Sundar, David S. Snyder, Jason Gotlib, Iskra Pusic, Vivian G. Oehler |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
business.industry
medicine.drug_class Fusion Proteins bcr-abl Myeloid leukemia Treatment options Chromosomal translocation Medical Oncology Blast Phase Philadelphia chromosome medicine.disease Translocation Genetic Tyrosine-kinase inhibitor Fusion gene Oncology Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Leukemia Myeloid Chronic-Phase Cancer research Humans Medicine Philadelphia Chromosome Chronic phase CML business |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 18:1385-1415 |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2020.0047 |
| Popis: | Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to aBCR-ABL1fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|